Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Subscribe To Our Newsletter & Stay Updated
